**ADAPT is a Clinical Study Designed with Patient Input**

ADAPT is a randomized, double-blind, placebo-controlled, multicenter phase 3 study to evaluate the efficacy, safety and tolerability of efgartigimod in patients with generalized myasthenia gravis (gMG).

<table>
<thead>
<tr>
<th>When asked, patients requested:</th>
<th>ADAPT Study Design:</th>
</tr>
</thead>
<tbody>
<tr>
<td>A study open to a broad range of patients</td>
<td>Patients who test positive for antibodies (AChR, MuSK, or LRP4) and those who test negative for antibodies (seronegative) may be eligible to participate. This is the first phase 3 study for gMG to include seronegative patients.</td>
</tr>
<tr>
<td>A therapy designed to target the underlying cause of gMG</td>
<td>Efgartigimod is thought to reduce the presence of antibodies that contribute to neuromuscular weakness in gMG.</td>
</tr>
<tr>
<td>To remain on current medications throughout the study</td>
<td>Efgartigimod or placebo will be administered on top of current gMG medications*.</td>
</tr>
<tr>
<td>Treatment that accounts for patient’s specific requirements/needs</td>
<td>Study drug will be given based on physician evaluation of your individual symptoms.</td>
</tr>
</tbody>
</table>

*If you take non-steroidal immunosuppressants (azathioprine, mycophenolate, methotrexate, etc.), steroids, and/or acetylcholinesterase inhibitors, you do not need to stop your current medications to participate in ADAPT. Other treatments – such as IVIg, PLEX, eculizumab, and rituximab – may impact the timing and/or eligibility for study participation.
Help contribute to the development of a potential treatment option for gMG

Who is eligible for the ADAPT gMG study?
If you are over 18 and have a diagnosis of gMG, you may be eligible to participate in this study.

Things you should know:

• This study is open to gMG patients, regardless of autoantibody status. This includes patients who test positive for specific autoantibodies against AChR, MuSK, and LRP4 - and to patients who test negative.

• You must be on a stable dose of your current gMG medications*.

• Your doctor will need to see if you meet these and other eligibility criteria before you can be enrolled.

• Patients who complete the study may be given the opportunity to receive efgartigimod in a year-long follow-up study.

More information is available by visiting [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and searching for NCT03669588

Talk to your doctor to see if you might be eligible
Sign up at [www.argenxMGstudy.com](http://www.argenxMGstudy.com) to be notified when a study site opens in your area.

Exploring New Approaches in gMG